1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Valuation
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
RGNA
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
—
—
Implied Upside vs Midpoint
Description
RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA, Inc., our U.S.-based holding entity. We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland). Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management. RegenLab is the holder of over 70 granted patents, covering proprietary blood-processing devices (Platelet Rich Plasma, or “PRP”), crosslinked scaffolds, combination products (PRP with Hyaluronic Acid (“HA”)), bone marrow–derived solutions, and bioengineered matrices designed for point-of-care preparation and safe, reproducible use across outpatient and surgical settings. We have numerous products across different stages of regulatory approval in both CE-MDR and FDA frameworks, including active PMA and 510(k) pathways. “CE-MDR” refers to the CE marking obtained pursuant to the European Union Medical Device Regulation (Regulation (EU) 2017/745) (the “EU MDR”). The “510(k) pathway” refers to the FDA’s premarket notification process under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, through which a manufacturer seeks to demonstrate that a medical device is substantially equivalent to a legally marketed predicate device for its intended use. The 510(k) pathway is the primary regulatory route for most Class I, Class II and certain Class III medical devices, whereby manufacturers submit a premarket notification demonstrating that the new device is substantially equivalent in intended use, technological characteristics, safety and effectiveness to a legally marketed predicate device already cleared by the FDA. A device is “FDA cleared” when the FDA has reviewed the applicable premarket submission (including a 510(k), as applicable) and issued a clearance determination permitting the device to be legally marketed and distributed in the United States for its cleared indications for use. “FDA clearance” differs from “FDA approval,” which generally refers to marketing authorization granted through the more rigorous FDA approval process required for high-risk devices under the FDA’s Premarket Approval process (“PMA”) pathway. With a growing body of clinical and economic evidence, our products have been evaluated in approximately 300 clinical studies supporting joint preservation, soft tissue healing, dermal rejuvenation, and urogenital regeneration. RegenLab has built a modular regenerative product platform that enables tailored solutions across multiple therapeutic areas, notably: ● A stratified osteoarthritis platform designed to address all Kellgren–Lawrence (“KL”) grades (II to IV) with standardized offerings, including: ● Arthrovisc, our CE-MDR product utilizing HA-alone syringes for Grade II KL; ● Regenkit, our CE-MDR and FDA cleared product utilizing PRP-only solutions for Grade II KL; ● Cellular Matrix, our CE-MDR product, with a PMA in process, integrating PRP with linear HA for Grade III KL; and ● RegenMatrix, our pipeline product, integrating PRP with crosslinked HA. ● An expanding wound care platform, anchored by RegenWound, our gel-based autologous product currently reimbursed by CMS in the U.S. for chronic wound management and under commercialization through key partnerships, as well as our newly EU-MDR certified Cellular Membrane product (also referred to herein as CellularWound). ● Emerging platforms targeting tissue repair and regenerative surgery, including bioresorbable electrospun implants, PRP-enhanced matrices, and next-generation gelation systems integrating calcium gluconate or tranexamic acid for hemostatic and anti-inflammatory applications. Through this vertically integrated model, RegenLab has achieved direct control over all critical functions — from core IP ownership, to R&D, device design, engineering & manufacturing, clinical validation, and regulatory execution — enabling us to deliver compliant, clinically validated, and scalable regenerative products in a rapidly evolving global market. RegenLab’s medical device products are commercialized through a mix of direct sales forces in key markets, including the United States, Switzerland, France, Germany and Spain and distribution partnerships. Our Products RegenLab is a global leader in autologous regenerative medicine, offering a fully integrated portfolio of standardized PRP, PRP-HA, and tissue engineering technologies across four major therapeutic domains: 1. Musculoskeletal (MSK) Regeneration 2. Advanced Wound Care 3. Medical Aesthetics / Dermatology 4. Women’s Health / Urogynecology RegenLab’s vertically integrated model extends beyond PRP to include crosslinked HA gels, nanofiber scaffolds, bioresorbable implants, and fibrin-based biomaterials, enabling a convergence of cell-based therapy and tissue engineering. Each of the four therapeutic platforms is built on a scalable, modular product suite, addressing disease severity and clinical workflow, which we believe opens up a combined global market opportunity exceeding $30 billion. --- We were formed as RegenLab USA LLC, a Delaware limited liability company, in April 2014, as a wholly owned subsidiary of Regen Lab S.A., a limited company domiciled in Switzerland (“RLS”), with RLS as a wholly owned subsidiary of Regen Lab Holding S.A., a limited company domiciled in Switzerland (“RLH”). In July 2025, we converted (the “Conversion”) to a Delaware corporation and changed our name to RegenLab USA, Inc. (“RLU”), by filing with the Secretary of State of Delaware a Certificate of Conversion from a limited liability company to a corporation. --- Our principal executive office is located at 95 Greene Street, Jersey City, NJ 07302, and our phone number is 1 (800) 220–9082. We maintain a website at https://regenlabusa.com/.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||